Stocks and Investing
Stocks and Investing
Thu, September 22, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, September 21, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Brian Cheng Initiated (ADCT) at Buy and Held Target at $5 on, Sep 21st, 2022
Brian Cheng of JP Morgan, Initiated "ADC Therapeutics SA" (ADCT) at Buy and Held Target at $5 on, Sep 21st, 2022.
Brian has made no other calls on ADCT in the last 4 months.
There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $11 on, Friday, September 9th, 2022
These are the ratings of the 2 analyists that currently disagree with Brian
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $21 on, Monday, September 19th, 2022
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $29 on, Wednesday, August 10th, 2022
Contributing Sources